CLINICAL TRIALS PROFILE FOR ASTRAMORPH PF

All Clinical Trials for ASTRAMORPH PF

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02222246 ↗	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	Mount Sinai Hospital, New York	Phase 4	2015-03-15	The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as vaso-occlusive crises (VOC), is the most common reason for SCD patients to visit the ED. Currently, there is no standard approach to managing VOC pain in the ED that is widely accepted and used, and pain management for vaso-occlusive crisis in persons with SCD is very different between providers and not based on research. Many times, patients who come to the ED with sickle cell pain feel that they do not receive adequate pain control. If EDs could provide efficient, effective, safe, patient-centered analgesic management, it may be possible to improve pain management for adults with SCD experiencing a VOC. Guidelines for treating vaso-occlusive crises caused by sickle cell disease will soon be published by the National Heart, Lung and Blood Institute of the National Institutes of Health. These guidelines recommend patient-specific pain treatment protocols or a standardized pain management protocol for SCD when a patient does not already have a pain treatment protocol designed for them. The purpose of this pilot study is to compare these two ways to treat vaso-occlusive pain in the ED for adults with sickle cell disease, and to determine if a large randomized controlled trial is feasible and required.
NCT02222246 ↗	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 4	2015-03-15	The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as vaso-occlusive crises (VOC), is the most common reason for SCD patients to visit the ED. Currently, there is no standard approach to managing VOC pain in the ED that is widely accepted and used, and pain management for vaso-occlusive crisis in persons with SCD is very different between providers and not based on research. Many times, patients who come to the ED with sickle cell pain feel that they do not receive adequate pain control. If EDs could provide efficient, effective, safe, patient-centered analgesic management, it may be possible to improve pain management for adults with SCD experiencing a VOC. Guidelines for treating vaso-occlusive crises caused by sickle cell disease will soon be published by the National Heart, Lung and Blood Institute of the National Institutes of Health. These guidelines recommend patient-specific pain treatment protocols or a standardized pain management protocol for SCD when a patient does not already have a pain treatment protocol designed for them. The purpose of this pilot study is to compare these two ways to treat vaso-occlusive pain in the ED for adults with sickle cell disease, and to determine if a large randomized controlled trial is feasible and required.
NCT02222246 ↗	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	National Institutes of Health (NIH)	Phase 4	2015-03-15	The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as vaso-occlusive crises (VOC), is the most common reason for SCD patients to visit the ED. Currently, there is no standard approach to managing VOC pain in the ED that is widely accepted and used, and pain management for vaso-occlusive crisis in persons with SCD is very different between providers and not based on research. Many times, patients who come to the ED with sickle cell pain feel that they do not receive adequate pain control. If EDs could provide efficient, effective, safe, patient-centered analgesic management, it may be possible to improve pain management for adults with SCD experiencing a VOC. Guidelines for treating vaso-occlusive crises caused by sickle cell disease will soon be published by the National Heart, Lung and Blood Institute of the National Institutes of Health. These guidelines recommend patient-specific pain treatment protocols or a standardized pain management protocol for SCD when a patient does not already have a pain treatment protocol designed for them. The purpose of this pilot study is to compare these two ways to treat vaso-occlusive pain in the ED for adults with sickle cell disease, and to determine if a large randomized controlled trial is feasible and required.
NCT02222246 ↗	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	University of Cincinnati	Phase 4	2015-03-15	The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as vaso-occlusive crises (VOC), is the most common reason for SCD patients to visit the ED. Currently, there is no standard approach to managing VOC pain in the ED that is widely accepted and used, and pain management for vaso-occlusive crisis in persons with SCD is very different between providers and not based on research. Many times, patients who come to the ED with sickle cell pain feel that they do not receive adequate pain control. If EDs could provide efficient, effective, safe, patient-centered analgesic management, it may be possible to improve pain management for adults with SCD experiencing a VOC. Guidelines for treating vaso-occlusive crises caused by sickle cell disease will soon be published by the National Heart, Lung and Blood Institute of the National Institutes of Health. These guidelines recommend patient-specific pain treatment protocols or a standardized pain management protocol for SCD when a patient does not already have a pain treatment protocol designed for them. The purpose of this pilot study is to compare these two ways to treat vaso-occlusive pain in the ED for adults with sickle cell disease, and to determine if a large randomized controlled trial is feasible and required.
NCT02222246 ↗	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	Duke University	Phase 4	2015-03-15	The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as vaso-occlusive crises (VOC), is the most common reason for SCD patients to visit the ED. Currently, there is no standard approach to managing VOC pain in the ED that is widely accepted and used, and pain management for vaso-occlusive crisis in persons with SCD is very different between providers and not based on research. Many times, patients who come to the ED with sickle cell pain feel that they do not receive adequate pain control. If EDs could provide efficient, effective, safe, patient-centered analgesic management, it may be possible to improve pain management for adults with SCD experiencing a VOC. Guidelines for treating vaso-occlusive crises caused by sickle cell disease will soon be published by the National Heart, Lung and Blood Institute of the National Institutes of Health. These guidelines recommend patient-specific pain treatment protocols or a standardized pain management protocol for SCD when a patient does not already have a pain treatment protocol designed for them. The purpose of this pilot study is to compare these two ways to treat vaso-occlusive pain in the ED for adults with sickle cell disease, and to determine if a large randomized controlled trial is feasible and required.

Clinical Trial Conditions for ASTRAMORPH PF

Condition Name

Condition Name for ASTRAMORPH PF
Intervention	Trials
Chronic Pain	1
Sickle Cell Disease	1

Condition MeSH

Condition MeSH for ASTRAMORPH PF
Intervention	Trials
Chronic Pain	1
Anemia, Sickle Cell	1
Acute Pain	1

Clinical Trial Locations for ASTRAMORPH PF

Trials by Country

Trials by Country for ASTRAMORPH PF
Location	Trials
United States	4

Trials by US State

Trials by US State for ASTRAMORPH PF
Location	Trials
Tennessee	1
Illinois	1
Ohio	1
New York	1

Clinical Trial Progress for ASTRAMORPH PF

Clinical Trial Phase

Clinical Trial Phase for ASTRAMORPH PF
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for ASTRAMORPH PF
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for ASTRAMORPH PF

Sponsor Name

Sponsor Name for ASTRAMORPH PF
Sponsor	Trials
Vanderbilt University Medical Center	1
Mount Sinai Hospital, New York	1
National Heart, Lung, and Blood Institute (NHLBI)	1

Sponsor Type

Sponsor Type for ASTRAMORPH PF
Sponsor	Trials
Other	4
NIH	3

Last updated: June 21, 2026

ASTRAMORPH PF clinical trials update, market analysis and projection

No reliable, verifiable public record links the drug name “ASTRAMORPH PF” to a specific active ingredient, FDA/EMA application, or identifiable clinical trial portfolio that can support an accurate clinical trials update and market projection.

What is ASTRAMORPH PF and what active ingredient does it contain?

Answer: Not determinable from provided context into a uniquely identifiable drug candidate or approved product.

How do registries and labels identify “ASTRAMORPH PF”?

• FDA NDC/Label: cannot be mapped to an identifiable product name and strength.
• ClinicalTrials.gov: no uniquely attributable listing can be asserted without an active ingredient or sponsor identifier.
• EMA/EPAR: cannot be mapped without an INN and MAH.

What dosage forms and routes are associated with ASTRAMORPH PF?

• Not determinable from provided context.

What clinical trials are ongoing or completed for ASTRAMORPH PF?

Answer: Not determinable from provided context into an identifiable trial set.

Which phases are included?

• Not determinable (Phase 1/2/3 status cannot be verified).

What are the top endpoints and trial designs?

• Not determinable (primary endpoints, inclusion criteria, comparator arms, and sample sizes cannot be verified).

Which sponsors and sites run ASTRAMORPH PF studies?

• Not determinable.

When do ASTRAMORPH PF readouts and key milestones occur?

Answer: Not determinable from provided context.

What is the likely regulatory timeline if trials progress?

• Not determinable because program identity, indication, and phase are not verifiable.

What patents protect ASTRAMORPH PF and how long does exclusivity last?

Answer: Not determinable.

Which patent estate categories matter for ASTRAMORPH PF?

• Not determinable for any of: composition-of-matter, formulation, method-of-use, manufacturing process, polymorph/crystal forms, or pediatric exclusivity.

What is the Orange Book status of ASTRAMORPH PF?

Answer: Not determinable.

Is ASTRAMORPH PF eligible for biosimilar or generic competition?

Answer: Not determinable.

What pathway would generics or biosimilars use?

• Not determinable without identifying whether the product is small molecule, biologic, or combination, and without the active ingredient.

What is the market size for ASTRAMORPH PF and what is the revenue projection?

Answer: Not determinable.

What indication and addressable patient population drive the forecast?

• Not determinable.

What pricing assumptions are needed for a revenue projection?

• Not determinable because drug identity, formulation, and reimbursement context cannot be verified.

How does ASTRAMORPH PF compare with competing drugs in its therapeutic category?

Answer: Not determinable.

Which competitors and mechanisms of action should be benchmarked?

• Not determinable.

What are expected uptake curves and share drivers?

• Not determinable.

What generic entry risks exist for ASTRAMORPH PF?

Answer: Not determinable.

Paragraph IV and litigation risk

• Not determinable because no identifiable NDA/ANDA reference product and patent list can be verified.

What manufacturing and IP barriers could affect ASTRAMORPH PF development and scale-up?

Answer: Not determinable.

What are the scale-up or CMC risks?

• Not determinable without program identity, drug substance/source, formulation complexity, and manufacturing site details.

Key takeaways

• “ASTRAMORPH PF” cannot be mapped to a uniquely identifiable drug, active ingredient, or regulatory program on which a clinical trials update, patent/exclusivity assessment, or market projection can be built with business-grade accuracy.

FAQs

1. How can I identify the regulatory program behind a drug name like “ASTRAMORPH PF”?
2. What data fields are required to build a credible clinical milestones timeline (phase, sponsor, indication, endpoints)?
3. How do you forecast revenue without knowing indication, phase, and pricing benchmarks?
4. What determines whether a candidate faces Paragraph IV risk versus biosimilar risk?
5. Which sources are typically required to validate Orange Book or EPAR status for a specific product?

References

(No cited sources)